Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Overcoming Target Driven Fratricide for T Cell Therapy.

Breman E, Demoulin B, Agaugué S, Mauën S, Michaux A, Springuel L, Houssa J, Huberty F, Jacques-Hespel C, Marchand C, Marijsse J, Nguyen T, Ramelot N, Violle B, Daro D, De Waele P, Gilham DE, Steenwinckel V.

Front Immunol. 2018 Dec 12;9:2940. doi: 10.3389/fimmu.2018.02940. eCollection 2018.

2.

Apabetalone downregulates factors and pathways associated with vascular calcification.

Gilham D, Tsujikawa LM, Sarsons CD, Halliday C, Wasiak S, Stotz SC, Jahagirdar R, Sweeney M, Johansson JO, Wong NCW, Kalantar-Zadeh K, Kulikowski E.

Atherosclerosis. 2019 Jan;280:75-84. doi: 10.1016/j.atherosclerosis.2018.11.002. Epub 2018 Nov 14.

3.

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S.

Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5.

PMID:
30396908
4.

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.

Kueberuwa G, Zheng W, Kalaitsidou M, Gilham DE, Hawkins RE.

J Vis Exp. 2018 Oct 16;(140). doi: 10.3791/58492.

5.

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.

Murad JM, Baumeister SH, Werner L, Daley H, Trébéden-Negre H, Reder J, Sentman CL, Gilham D, Lehmann F, Snykers S, Sentman ML, Wade T, Schmucker A, Fanger MW, Dranoff G, Ritz J, Nikiforow S.

Cytotherapy. 2018 Jul;20(7):952-963. doi: 10.1016/j.jcyt.2018.05.001. Epub 2018 Jun 29.

PMID:
30180944
6.

Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.

Owens GL, Price MJ, Cheadle EJ, Hawkins RE, Gilham DE, Edmondson RJ.

Cancer Immunol Immunother. 2018 Oct;67(10):1519-1531. doi: 10.1007/s00262-018-2211-3. Epub 2018 Jul 23.

7.

Benefit of Apabetalone on Plasma Proteins in Renal Disease.

Wasiak S, Tsujikawa LM, Halliday C, Stotz SC, Gilham D, Jahagirdar R, Kalantar-Zadeh K, Robson R, Sweeney M, Johansson JO, Wong NC, Kulikowski E.

Kidney Int Rep. 2017 Dec 8;3(3):711-721. doi: 10.1016/j.ekir.2017.12.001. eCollection 2018 May.

8.

NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.

Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML.

Haematologica. 2018 Sep;103(9):e424-e426. doi: 10.3324/haematol.2017.186742. Epub 2018 Apr 27. No abstract available.

9.

Celyad's novel CAR T-cell therapy for solid malignancies.

Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van Den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF.

Curr Res Transl Med. 2018 May;66(2):53-56. doi: 10.1016/j.retram.2018.03.001. Epub 2018 Apr 4.

PMID:
29625833
10.

CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity.

Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE, Gilham DE.

Mol Ther Oncolytics. 2017 Dec 19;8:41-51. doi: 10.1016/j.omto.2017.12.003. eCollection 2018 Mar 30.

11.

Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.

Owens GL, Sheard VE, Kalaitsidou M, Blount D, Lad Y, Cheadle EJ, Edmondson RJ, Kooner G, Gilham DE, Harrop R.

J Immunother. 2018 Apr;41(3):130-140. doi: 10.1097/CJI.0000000000000203.

12.

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types.

Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF.

BMJ Open. 2017 Nov 12;7(11):e017075. doi: 10.1136/bmjopen-2017-017075.

13.

RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.

Jahagirdar R, Attwell S, Marusic S, Bendele A, Shenoy N, McLure KG, Gilham D, Norek K, Hansen HC, Yu R, Tobin J, Wagner GS, Young PR, Wong NCW, Kulikowski E.

Mol Pharmacol. 2017 Dec;92(6):694-706. doi: 10.1124/mol.117.110379. Epub 2017 Sep 29.

PMID:
28974538
14.

'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.

Gilham DE, Maher J.

Immunotherapy. 2017 Aug;9(9):723-733. doi: 10.2217/imt-2017-0045. Epub 2017 Aug 3. Review.

PMID:
28771104
15.

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.

Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, Byatte AJ, Kirillova N, Valle JW, Sharma SK, Chester KA, Westwood NB, Halford SER, Nabarro S, Wan S, Austin E, Hawkins RE.

Cancer Immunol Immunother. 2017 Nov;66(11):1425-1436. doi: 10.1007/s00262-017-2034-7. Epub 2017 Jun 28.

16.

Exploiting natural killer group 2D receptors for CAR T-cell therapy.

Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S.

Future Oncol. 2017 Aug;13(18):1593-1605. doi: 10.2217/fon-2017-0102. Epub 2017 Jun 14. Review.

17.

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).

Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Calosing C, Jahagirdar R, Johansson J, Sweeney M, Wong NC, Kulikowski E.

J Cardiovasc Transl Res. 2017 Aug;10(4):337-347. doi: 10.1007/s12265-017-9755-z. Epub 2017 May 31.

18.

CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo.

Kueberuwa G, Gornall H, Alcantar-Orozco EM, Bouvier D, Kapacee ZA, Hawkins RE, Gilham DE.

J Immunother Cancer. 2017 Feb 21;5:14. doi: 10.1186/s40425-017-0216-7. eCollection 2017.

19.

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes.

Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Norek K, Patel RG, McLure KG, Young PR, Gordon A, Kulikowski E, Johansson J, Sweeney M, Wong NC.

Data Brief. 2016 Jul 29;8:1280-8. doi: 10.1016/j.dib.2016.07.047. eCollection 2016 Sep.

20.

Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57].

Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, Kulikowski E, Johansson J, Sweeney M, Wong NC.

Atherosclerosis. 2016 Oct;253:345. doi: 10.1016/j.atherosclerosis.2016.05.012. Epub 2016 May 20. No abstract available.

21.

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease.

Gilham D, Wasiak S, Tsujikawa LM, Halliday C, Norek K, Patel RG, Kulikowski E, Johansson J, Sweeney M, Wong NC, Gordon A, McLure K, Young P.

Atherosclerosis. 2016 Apr;247:48-57. doi: 10.1016/j.atherosclerosis.2016.01.036. Epub 2016 Jan 22. Erratum in: Atherosclerosis. 2016 Oct;253:345.

22.

CAR T-cell therapy: toxicity and the relevance of preclinical models.

Kalaitsidou M, Kueberuwa G, Schütt A, Gilham DE.

Immunotherapy. 2015;7(5):487-97. doi: 10.2217/imt.14.123. Review.

PMID:
26065475
23.

Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma.

Baldan V, Griffiths R, Hawkins RE, Gilham DE.

Br J Cancer. 2015 Apr 28;112(9):1510-8. doi: 10.1038/bjc.2015.96. Epub 2015 Mar 17.

24.

Adoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.

Gilham DE, Anderson J, Bridgeman JS, Hawkins RE, Exley MA, Stauss H, Maher J, Pule M, Sewell AK, Bendle G, Lee S, Qasim W, Thrasher A, Morris E.

Hum Gene Ther. 2015 May;26(5):276-85. doi: 10.1089/hum.2015.024. Review.

25.

In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.

Shablak A, Gilham DE, Hawkins RE, Elkord E.

Expert Opin Pharmacother. 2014 Aug;15(11):1489-99. doi: 10.1517/14656566.2014.920824. Epub 2014 Jun 3.

PMID:
24890457
26.

Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.

Cheadle EJ, Sheard V, Rothwell DG, Bridgeman JS, Ashton G, Hanson V, Mansoor AW, Hawkins RE, Gilham DE.

J Immunol. 2014 Apr 15;192(8):3654-65. doi: 10.4049/jimmunol.1302148. Epub 2014 Mar 12.

27.

Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor.

John LB, Chee TM, Gilham DE, Darcy PK.

Methods Mol Biol. 2014;1139:177-87. doi: 10.1007/978-1-4939-0345-0_16.

PMID:
24619680
28.

CAR T cells: driving the road from the laboratory to the clinic.

Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE.

Immunol Rev. 2014 Jan;257(1):91-106. doi: 10.1111/imr.12126. Review.

PMID:
24329792
29.

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.

Guest RD, Kirillova N, Mowbray S, Gornall H, Rothwell DG, Cheadle EJ, Austin E, Smith K, Watt SM, Kühlcke K, Westwood N, Thistlethwaite F, Hawkins RE, Gilham DE.

Cancer Immunol Immunother. 2014 Feb;63(2):133-45. doi: 10.1007/s00262-013-1492-9. Epub 2013 Nov 5.

PMID:
24190544
30.

CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.

Bridgeman JS, Ladell K, Sheard VE, Miners K, Hawkins RE, Price DA, Gilham DE.

Clin Exp Immunol. 2014 Feb;175(2):258-67. doi: 10.1111/cei.12216.

31.

Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol.

Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG.

Hum Gene Ther Methods. 2013 Dec;24(6):381-91. doi: 10.1089/hgtb.2013.068. Epub 2013 Oct 11.

PMID:
24028672
32.

Targeting T cells to tumor: exploiting the chimeric antibody receptor.

Gilham DE, Cheadle EJ.

Immunotherapy. 2013 Sep;5(9):927-9. doi: 10.2217/imt.13.92.

PMID:
23998728
33.

Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer.

Alcantar-Orozco EM, Gornall H, Baldan V, Hawkins RE, Gilham DE.

Hum Gene Ther Methods. 2013 Oct;24(5):310-20. doi: 10.1089/hgtb.2013.022. Epub 2013 Aug 24.

34.

Chimeric antigen receptors for T-cell based therapy.

Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C, Schooten E, Lamers C, Abken H, Debets R, Gilham DE.

Methods Mol Biol. 2012;907:645-66. doi: 10.1007/978-1-61779-974-7_36.

PMID:
22907378
35.
36.

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

Gilham DE, Debets R, Pule M, Hawkins RE, Abken H.

Trends Mol Med. 2012 Jul;18(7):377-84. doi: 10.1016/j.molmed.2012.04.009. Epub 2012 May 19. Review.

PMID:
22613370
37.

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.

Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG.

Cancer Immunol Immunother. 2012 Jul;61(7):953-62. doi: 10.1007/s00262-012-1254-0. Epub 2012 Apr 22. Review.

PMID:
22527245
38.

Metabolic control by S6 kinases depends on dietary lipids.

Castañeda TR, Abplanalp W, Um SH, Pfluger PT, Schrott B, Brown K, Grant E, Carnevalli L, Benoit SC, Morgan DA, Gilham D, Hui DY, Rahmouni K, Thomas G, Kozma SC, Clegg DJ, Tschöp MH.

PLoS One. 2012;7(3):e32631. doi: 10.1371/journal.pone.0032631. Epub 2012 Mar 7.

39.

Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.

Marr LA, Gilham DE, Campbell JD, Fraser AR.

Clin Exp Immunol. 2012 Feb;167(2):216-25. doi: 10.1111/j.1365-2249.2011.04517.x. Review.

40.

Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells.

Cheadle EJ, Rothwell DG, Bridgeman JS, Sheard VE, Hawkins RE, Gilham DE.

Gene Ther. 2012 Nov;19(11):1114-20. doi: 10.1038/gt.2011.192. Epub 2011 Dec 1.

PMID:
22130449
41.

Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.

Castro FV, Al-Muftah M, Mulryan K, Jiang HR, Drijfhout JW, Ali S, Rutkowski AJ, Kalaitsidou M, Gilham DE, Stern PL.

Cancer Immunol Immunother. 2012 Jul;61(7):1005-18. doi: 10.1007/s00262-011-1167-3. Epub 2011 Nov 30.

PMID:
22127365
42.

Effective adoptive T-cell therapy for cancer in the absence of host lymphodepletion.

Gilham DE.

Immunotherapy. 2011 Feb;3(2):177-9. doi: 10.2217/imt.10.115.

PMID:
21322758
43.

T regulatory cells in cancer: recent advances and therapeutic potential.

Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE.

Expert Opin Biol Ther. 2010 Nov;10(11):1573-86. doi: 10.1517/14712598.2010.529126. Review.

PMID:
20955112
44.

Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding.

Waddington SN, Crossley R, Sheard V, Howe SJ, Buckley SM, Coughlan L, Gilham DE, Hawkins RE, McKay TR.

Mol Ther. 2010 Dec;18(12):2104-11. doi: 10.1038/mt.2010.174. Epub 2010 Aug 24.

45.

Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent.

Rothwell DG, Crossley R, Bridgeman JS, Sheard V, Zhang Y, Sharp TV, Hawkins RE, Gilham DE, McKay TR.

Hum Gene Ther. 2010 Nov;21(11):1631-7. doi: 10.1089/hum.2009.197.

PMID:
20528679
46.

The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.

Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE.

J Immunol. 2010 Jun 15;184(12):6938-49. doi: 10.4049/jimmunol.0901766. Epub 2010 May 17.

47.

Development of adoptive cell therapy for cancer: a clinical perspective.

Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium.

Hum Gene Ther. 2010 Jun;21(6):665-72. doi: 10.1089/hum.2010.086. Review.

PMID:
20408760
48.

Building better chimeric antigen receptors for adoptive T cell therapy.

Bridgeman JS, Hawkins RE, Hombach AA, Abken H, Gilham DE.

Curr Gene Ther. 2010 Apr;10(2):77-90. Review.

PMID:
20222863
49.

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE.

J Immunol. 2010 Feb 15;184(4):1885-96. doi: 10.4049/jimmunol.0901440. Epub 2010 Jan 20.

50.

Supplemental Content

Loading ...
Support Center